Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Australian natural skincare company Skin Elements (SKN) has secured a $20 million funding facility with LDA Capital
  • Under the agreement, Skin Elements will issue shares to LDA Capital over the next three years at a floor price determined by Skin Elements
  • Funds from the agreement will give the company ready access to additional equity to support both its growth into new markets and existing channels
  • On the market, Skin Elements last traded at 10 cents per share

Skin Elements (SKN) has secured a $20 million funding facility with LDA Capital.

The parties have signed a put option agreement, which will see LDA provide Skin Elements up to $20 million in committed equity capital over the next 36 months.

Under the agreement, Skin Elements will issue shares to LDA Capital over the next three years at a floor price determined by Skin Elements and will receive funds for the issue of those shares.

Funds from the agreement will give the company ready access to additional equity to support both its growth into new markets and existing channels.

Last year, the natural skincare company applied for a Therapeutic Goods Administration (TGA) registration for its sanitising disinfectant, Invisi Shield — a hospital-grade disinfectant.

“Successful registration with the TGA will allow the company to make more
detailed and specific product and label claims in respect to Invisi Shield which has the potential to open up significant new commercial-scale sales and distribution opportunities,” the company explained to the market.

“We are excited to have secured this $20 million equity funding facility from LDA Capital,” Chairman Peter Malone said.

“LDA Capital has a track record of providing funding to help emerging growth
companies achieve their business goals, and we are delighted to see that LDA Capital shares the same positive view on the global growth potential of our Invisi Shield sanitising disinfectant and our range of natural skincare products as we do,” he added.

On the market, Skin Elements is suspended and last traded at 10 cents per share.

SKN by the numbers
More From The Market Herald
Amplia Therapeutics - CEO and MD, John Lambert

" Amplia Therapeutics (ASX:ATX) granted $2.1 million R&D cash flow loan

Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan.
Creso Pharma (ASX:CPH) - Creso Pharma

" Creso Pharma’s (ASX:CPH) Halucenex secures Dealer’s Licence amendment

Halucenex Life Sciences, a subsidiary of Creso Pharma (CPH), has secured an amendment to its Controlled Drugs and Substances Dealer’s Licence.

" Immutep (IMM) treats first five patients in solid tumour study

Immutep (IMM) has treated five patients in its study evaluating eftilagimod (efti) alpha in conjunction with standard of care chemotherapy.
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) granted ethics approval for chronic pain trial

Zelira Therapeutics (ZLD) has received ethics approval for its Phase 2a clinical trial for chronic pain.